AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab
Wanying Qin, Xudong Fei, Renfang Shi, Yuchen Zhou, Jiajie Tang, Yizhe Liu, Yi Zhu, Liya Suo, Weijia Liao · 2026
Read AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab by Wanying Qin, Xudong Fei, Renfang Shi, Yuchen Zhou, Jiajie Tang, Yizhe Liu, Yi Zhu, Liya Suo, Weijia Liao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13290531.txt.
Description
A three-part blood-and-burden score sorts liver cancer patients by outlook before treatment starts, Wanying Qin and colleagues report in 2026. The patients had unresectable hepatocellular carcinoma treated with chemoembolization plus the immunotherapy sintilimab and the targeted drug bevacizumab.
Using records for 176 patients from two institutions treated between March 2021 and May 2024, the team tested pretreatment measures against survival. Alpha-fetoprotein, alkaline phosphatase, and a tumor burden score each predicted survival on their own, so the authors combined them into the AAT score. It separated patients into low-, middle-, and high-risk groups whose two-year survival differed sharply, and it beat any single factor in both the training and validation cohorts. Qin and colleagues offer it for personalizing decisions in this combination therapy.
Catalog record
| CREATOR | Wanying Qin, Xudong Fei, Renfang Shi, Yuchen Zhou, Jiajie Tang, Yizhe Liu, Yi Zhu, Liya Suo, Weijia Liao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37542 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |